Nanotechnology in Cancer Drug Delivery and Selective Targeting

Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment.

[1]  Stasia A. Anderson,et al.  Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .

[2]  Marilena Loizidou,et al.  Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. , 2009, Trends in pharmacological sciences.

[3]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[4]  K. Nguyen.  Targeted Nanoparticles for Cancer Therapy: Promises and Challenges , 2011 .

[5]  Ick Chan Kwon,et al.  Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Neil Desai,et al.  Challenges in Development of Nanoparticle-Based Therapeutics , 2012, The AAPS Journal.

[7]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  T. Minko,et al.  Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[9]  P. Choong,et al.  Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy , 2006, Cancer Cell International.

[10]  Matthew R Cooperberg,et al.  Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells , 2004, Cancer Research.

[11]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[12]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[13]  Shiladitya Sengupta,et al.  Nanotechnology-mediated targeting of tumor angiogenesis , 2011, Vascular cell.

[14]  Michihiro Nakamura,et al.  Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles , 2007, International journal of cancer.

[15]  F. Szoka,et al.  Chemical approaches to triggerable lipid vesicles for drug and gene delivery. , 2003, Accounts of chemical research.

[16]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[17]  R. Brown,et al.  Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs , 1999, Expert Reviews in Molecular Medicine.

[18]  G. Ali Mansoori,et al.  Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead , 2007 .

[19]  Dai Fukumura,et al.  Imaging angiogenesis and the microenvironment   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[20]  G. Mansoori,et al.  Utilizing the folate receptor for active targeting of cancer nanotherapeutics , 2012, Nano reviews.

[21]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[22]  F. Hall,et al.  Nanotechnology blooms, at last (Review). , 2005, Oncology reports.

[23]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[24]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[25]  P. Rubin,et al.  Microcirculation of tumors Part I: Anatomy, function, and necrosis , 1966 .

[26]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[27]  F. Szoka,et al.  Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. , 2001, Cancer research.

[28]  G. Russell-Jones,et al.  Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent , 2012 .

[29]  M. Kamal,et al.  Nanotechnology-based approaches in anticancer research , 2012, International journal of nanomedicine.

[30]  L. Akslen,et al.  Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.

[31]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[32]  S. Dharap,et al.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Prato,et al.  Applications of carbon nanotubes in drug delivery. , 2005, Current opinion in chemical biology.

[34]  W. Ouwehand,et al.  Human Antibody Fragments Specific for Human Blood Group Antigens from a Phage Display Library , 1993, Bio/Technology.

[35]  D. Lasič,et al.  Doxorubicin in sterically stabilized liposomes , 1996, Nature.

[36]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[37]  E. Ruoslahti.  Cell adhesion and tumor metastasis. , 1994, Princess Takamatsu symposia.

[38]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[39]  Mark E. Davis,et al.  Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. , 2003, Bioconjugate chemistry.

[40]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[41]  Md. Lutful Amin.  P-glycoprotein Inhibition for Optimal Drug Delivery , 2013, Drug target insights.

[42]  J. Panyam,et al.  Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[43]  Jayanth Panyam,et al.  Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. , 2009, Biomaterials.

[44]  J. Lieberman,et al.  Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 , 2007, Proceedings of the National Academy of Sciences.

[45]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[48]  Joseph D. Andrade,et al.  Protein—surface interactions in the presence of polyethylene oxide , 1991 .

[49]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[50]  W. Tan,et al.  Ultra-small water-dispersible fluorescent chitosan nanoparticles: synthesis, characterization and specific targeting. , 2009, Chemical communications.

[51]  I. Pastan,et al.  Genetic analysis of the multidrug transporter. , 1995, Annual review of genetics.

[52]  Samuel A Wickline,et al.  Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy , 2008, Magnetic resonance in medicine.

[53]  Yoshinobu Fukumori,et al.  Nanoparticles for cancer therapy and diagnosis , 2006 .

[54]  R. Weichselbaum,et al.  Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells , 2003, Journal of Cell Science.

[55]  J. Kreuter,et al.  Improved delivery of methoxsalen. , 1979, Journal of pharmaceutical sciences.

[56]  R. Gurny,et al.  Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  S. Sudarshan,et al.  In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer , 2005, Cancer Gene Therapy.

[58]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[60]  E. Jones,et al.  HLA-B27 and disease pathogenesis: new structural and functional insights , 1999, Expert Reviews in Molecular Medicine.

[61]  Kinam Park.  Nanotechnology: What it can do for drug delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[62]  M. Chaplain,et al.  Mathematical Modelling of Angiogenesis , 2000, Journal of Neuro-Oncology.

[63]  P. Stauffer,et al.  Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. , 1994, Cancer research.

[64]  T. Park,et al.  LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. , 2008, Bioconjugate chemistry.

[65]  M. Jeffers,et al.  Anti-angiogenic therapy as a cancer treatment paradigm. , 2005, Current medicinal chemistry. Anti-cancer agents.

[66]  G. Barratt,et al.  Colloidal drug carriers: achievements and perspectives , 2003, Cellular and Molecular Life Sciences CMLS.

[67]  K. Kono,et al.  Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. , 2000, Bioconjugate chemistry.

[68]  M. Yatvin,et al.  pH-sensitive liposomes: possible clinical implications. , 1980, Science.

[69]  C. Myers,et al.  Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment , 2003, Breast Cancer Research.

[70]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[71]  E. Solary,et al.  Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. , 1997, Journal of the National Cancer Institute.

[72]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[73]  J. Kos,et al.  Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. , 2009, International journal of pharmaceutics.

[74]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[75]  K. B. Sutradhar,et al.  Nanoemulsions: increasing possibilities in drug delivery , 2013 .

[76]  Seymour,et al.  Control of tumour vascular permeability. , 1998, Advanced drug delivery reviews.

[77]  Tae Gwan Park,et al.  Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[78]  T. Tsuruo,et al.  Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[79]  T. Mandal,et al.  Engineered nanoparticles in cancer therapy. , 2007, Recent patents on drug delivery & formulation.

[80]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  E. Frenkel,et al.  Nanoparticles for drug delivery in cancer treatment. , 2008, Urologic oncology.

[82]  Robert Langer,et al.  Small-scale systems for in vivo drug delivery , 2003, Nature Biotechnology.

[83]  G. Hughes.  Nanostructure-mediated drug delivery. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[84]  Jie Pan,et al.  Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. , 2010, Biomaterials.

[85]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[86]  S. Hochwald,et al.  Nanoparticle delivery for metastatic breast cancer. , 2012, Maturitas.

[87]  F. Yuan,et al.  Transvascular drug delivery in solid tumors. , 1998, Seminars in radiation oncology.

[88]  T. Xu,et al.  Targeting cancer cells with biotin-dendrimer conjugates. , 2009, European journal of medicinal chemistry.

[89]  H. Ueno,et al.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.

[90]  Philippe Shubik,et al.  Vascularization of tumors: A review , 2004, Journal of Cancer Research and Clinical Oncology.

[91]  A. Kabanov,et al.  Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. , 1996, British Journal of Cancer.

[92]  Anil K Patri,et al.  Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. , 2005, Advanced drug delivery reviews.

[93]  Shuming Nie,et al.  Emerging use of nanoparticles in diagnosis and treatment of breast cancer. , 2006, The Lancet. Oncology.

[94]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[95]  Shaker A Mousa,et al.  Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. , 2010, Pharmacology & therapeutics.

[96]  Thommey P. Thomas,et al.  Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.

[97]  M. Cristea,et al.  Polymeric micelles for oral drug delivery: Why and how , 2004 .

[98]  S. Mousa,et al.  Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications , 2011, Cancers.

[99]  Gang Zhao,et al.  Molecular targeting of liposomal nanoparticles to tumor microenvironment , 2012, International journal of nanomedicine.

[100]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[101]  Audrey Player,et al.  Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[102]  D. Kerr,et al.  Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.

[103]  Zhuang Liu,et al.  Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.

[104]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[105]  J. Marks.  Selection of internalizing antibodies for drug delivery. , 2004, Methods in molecular biology.

[106]  Jason Coleman,et al.  Emerging technologies of polymeric nanoparticles in cancer drug delivery , 2011 .

[107]  Linda K. Molnar,et al.  Strategic workshops on cancer nanotechnology. , 2010, Cancer research.

[108]  L. Qin,et al.  Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. , 2013, Journal of biomedical nanotechnology.

[109]  T. Horibe,et al.  A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells , 2011, BMC Cancer.

[110]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[111]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[112]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[113]  D. Peer,et al.  Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.

[114]  T. Wagner,et al.  Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor , 2004, Cancer Gene Therapy.

[115]  K. Strebhardt,et al.  Highly Specific HER2-mediated Cellular Uptake of Antibody-modified Nanoparticles in Tumour Cells , 2004, Journal of drug targeting.

[116]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[117]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.